Seniha Basaran

Abstract This study evaluates the effect of molnupiravir on clinical improvement, viral clearance and antibody responses of COVID-19 patients who previously developed immunity through vaccination or prior infection. This multi-center, prospective, observational study included all mild adult COVID-19 cases for whom molnupiravir was recommended during the study period. The primary outcome was hospitalization, death or new oxygen need due to COVID-19 within 28 days of follow-up.

ABSTRACT Streptococcus pyogenes (Group A Streptococcus) is an aerobic, gram-positive bacterium responsible for various infections such as pharyngitis, cellulitis, erysipelas, and necrotizing fasciitis. Though it rarely affects the lower respiratory tract, it can, in uncommon cases, cause community-acquired pneumonia. This study presents a rare case of rapidly progressing pneumonia caused by S. pyogenes, complicated by empyema.